Collective Strategies to Enhance Proportionate Enrollment

Topics Included: Access to Clinical Trials, Patient Engagement, Recruitment, Regulatory Submissions + Approvals, Site Planning

The Collective Strategies to Enhance Proportionate Enrollment project focuses on improving accountability, clarity, and communication across clinical trials partner groups to support more effective recruitment, enrollment, and retention practices. This effort seeks to understand and address the challenges, expectations, and needs of each group involved in clinical trials, including contract research organizations, patient organizations, sites, and sponsors.

By fostering action-focused and unified engagement throughout the clinical trials process, the project aims to identify practical solutions that help plan, design, and execute trials better positioned to recruit and retain participants who reflect the epidemiology and scientific evidence of the disease under study. These efforts will support the generation of reliable, relevant, and robust data to inform the development of safe and effective medical products for all populations.

Key Takeaways

Resources

Access to Clinical Trials | CTTI News

Report Now Available: Virtual Public Workshop to Enhance Clinical Study Diversity

The report of the two-day virtual public workshop to enhance clinical study diversity, convened by the U.S. Food and Drug Administration (FDA) in collaboration with the Clinical Trials Transformation Initiative...

Patient Engagement | Recommendations

Increasing Diversity in Clinical Trials

Increasing Diversity in Clinical Trials

Access to Clinical Trials | CTTI News

CTTI Publication Investigates Organizational Practices to Promote Diversity and Inclusion in Clinical Trials

A new CTTI publication, published in the Journal of Clinical Pharmacology & Therapeutics, investigates organizational-level practices for enhancing diversity and inclusion in clinical trials as one component of advancing health...

Access to Clinical Trials | CTTI News

CTTI Holds Meeting to Discuss the Systemic Changes Needed to Increase Diversity in Clinical Trials

The Clinical Trials Transformation Initiative (CTTI) held a two-day multi-stakeholder expert meeting on Oct. 12 & 21 to discuss the systemic changes needed to ensure that U.S. clinical trials better...

Patient Engagement

Diversity in Clinical Trials

The underrepresentation of diverse populations in clinical trials creates knowledge gaps about the risks and benefits of drugs and devices and undermines public trust in research.

Formats

Stage of Trial

Report Now Available: Virtual Public Workshop to Enhance Clinical Study Diversity

The report of the two-day virtual public workshop to enhance clinical study diversity, convened by the U.S. Food and Drug Administration (FDA) in collaboration with the Clinical Trials Transformation Initiative (CTTI), is now available. The workshop was held on November 29 and 30, 2023 with more than 2,600 global attendees. 

The workshop solicited input on strategies and considerations for increasing the enrollment of historically underrepresented populations in clinical studies and encouraging clinical study participation that reflects the prevalence of diseases or conditions among demographic subgroups. Speakers and panelists included representatives from the FDA and other federal agencies, academia, medical device and pharmaceutical sponsors, patients and patient advocacy groups, and research study teams. 

The workshop fulfilled a requirement under section 3603 of the Food and Drug Omnibus Reform Act of 2022 (FDORA). View the recording and slide deck to learn more. 

CTTI Publication Investigates Organizational Practices to Promote Diversity and Inclusion in Clinical Trials

A new CTTI publication, published in the Journal of Clinical Pharmacology & Therapeutics, investigates organizational-level practices for enhancing diversity and inclusion in clinical trials as one component of advancing health equity and improving health outcomes. When clinical trial participants do not reflect the populations that will use the medical product, it can limit our understanding of the safety and efficacy of the investigational medical product, restrict the availability of evidence-based treatment guidelines for vulnerable populations disproportionally burdened by disease, and delay access to innovative and potentially life-extending therapies.  

CTTI interviewed 36 senior-level leaders at 20 organizations that conduct clinical trials to gather perspectives on strategies to support diversity and inclusion in clinical research. Based on these interviews and a 2-day meeting with 53 experts, CTTI identified four key action areas to implement sustainable, organizational-level practices: commitment, partnerships, accountability, and resources. To improve equitable access and increase diversity in clinical trial populations, CTTI suggests making diversity and inclusion in clinical trials an organizational priority and defining responsibility for these efforts, establishing and maintaining bi-directional community partnerships, and allocating organizational resources that support diversity and inclusion in clinical research. The CTTI Diversity Project Team is using the findings from this research to develop recommendations and a tool for institutions to use to initiate or enhance their diversity and inclusion efforts. 

CTTI Holds Meeting to Discuss the Systemic Changes Needed to Increase Diversity in Clinical Trials

The Clinical Trials Transformation Initiative (CTTI) held a two-day multi-stakeholder expert meeting on Oct. 12 & 21 to discuss the systemic changes needed to ensure that U.S. clinical trials better meet the needs of diverse populations, including racial minorities, ethnic minorities, and women. At the meeting, leaders and key stakeholders from across the clinical trials ecosystem participated in an engaging forum, informative discussions, and lively breakout sessions that shed more light on new solutions for sharing information and ensuring sufficient resource allocation to diversity, equity, and inclusion initiatives.

Meeting attendees also identified some important themes and identified opportunities to increase diversity in clinical trials:

  • The benefits are indisputable. Including a diverse population in clinical trials improves the quality of science, enhances patient trust, increases patient recruitment and retention, and improves clinical care for all patients.
  • A culture shift is needed. Organizations need to ingrain diversity, equity, and inclusion initiatives into their portfolio-level strategy and within their overall mission. They should foster bi-directional community partnerships and directly engage patients in the design and planning of clinical trials and diversity efforts from the very beginning.
  • This is a full group effort. Increasing diversity in clinical trials is a multi-stakeholder effort that will take all groups working together to achieve goals of clinical trial populations representing the populations who are affected by disease.
  • There is important work ahead of us. Meeting attendees provided feedback on CTTI’s draft maturity model, helping to create a better public resource. Suggested additions included a focus on values and guidelines that are generalizable to a wide variety of stakeholders, not just industry stakeholders, and more guidance on how organizations can measure their progress through the maturity model.

CTTI is now using these findings – along with other research results and multi-stakeholder discussions – to develop recommendations and resources for release in early 2022. The project team may host additional webinars focusing on case studies and implementation of resources.

Diversity in Clinical Trials

Topics Included: Access to Clinical Trials, Patient Engagement

The underrepresentation of diverse populations in clinical trials creates critical knowledge gaps about the safety and effectiveness of medical products—and erodes public trust in research. To help change this, CTTI conducted a project aimed at improving access to clinical trials and increasing the inclusion of underrepresented populations. The resulting recommendations and resources are designed to help organizations implement practical, system-level changes that lead to more diverse participation and research findings that better reflect the needs of all people.

Resources

Site Planning

Collective Strategies to Enhance Proportionate Enrollment

The Collective Strategies to Enhance Proportionate Enrollment project focuses on improving accountability, clarity, and communication across clinical trials partner groups to support more effective recruitment, enrollment, and retention practices. This...

Access to Clinical Trials | CTTI News

Report Now Available: Virtual Public Workshop to Enhance Clinical Study Diversity

The report of the two-day virtual public workshop to enhance clinical study diversity, convened by the U.S. Food and Drug Administration (FDA) in collaboration with the Clinical Trials Transformation Initiative...

Patient Engagement | Recommendations

Increasing Diversity in Clinical Trials

Increasing Diversity in Clinical Trials

Access to Clinical Trials | CTTI News

CTTI Publication Investigates Organizational Practices to Promote Diversity and Inclusion in Clinical Trials

A new CTTI publication, published in the Journal of Clinical Pharmacology & Therapeutics, investigates organizational-level practices for enhancing diversity and inclusion in clinical trials as one component of advancing health...

Access to Clinical Trials | CTTI News

CTTI Holds Meeting to Discuss the Systemic Changes Needed to Increase Diversity in Clinical Trials

The Clinical Trials Transformation Initiative (CTTI) held a two-day multi-stakeholder expert meeting on Oct. 12 & 21 to discuss the systemic changes needed to ensure that U.S. clinical trials better...

Patient Engagement

Diversity in Clinical Trials

The underrepresentation of diverse populations in clinical trials creates knowledge gaps about the risks and benefits of drugs and devices and undermines public trust in research.

Formats

Stage of Trial